A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/16 (2006.01) A61K 31/337 (2006.01) A61K 31/34 (2006.01) A61K 31/4192 (2006.01) A61K 31/4196 (2006.01) A61K 31/435 (2006.01) A61K 45/06 (2006.01) A61P 35/00 (2006.01)
Patent
CA 2740571
This invention is based on the discovery that the administration of a sphingo sine- 1- phosphate receptor antagonist (SIP) and at least one chemotherapeutic agent selected from the the group of antimicrotubule agents provides an unexpectedly su-perior treatment for cancer. Antimicrobial agents such as the taxane compounds are known in the art, for example, paclitaxel (available as TAXOL® from Bristol-Myers Squibb, Princeton, NJ.), docetaxel (available as TAXOTERE® from Sanofi-aventis, Bridgewater, NJ.) and the like and other compounds that act as antimicrotubule agents, such as Vincristine (ONCOVIN®, VIN-CASAR PFS®, VCR), Vinblastin (VELBAN®, VELSAR® and Vinorelbine, and similar compounds. The present invention also provides methods of modulating the growth of selected cell populations, such as cancer cells, by administering a therapeutically effective amount of at least one sphingosine-1 -phosphate 1(S1P1R) receptor antagonists, and at least one antimicrotubule agent.
La présente invention concerne la découverte selon laquelle ladministration dun antagoniste du récepteur de la sphingosine-1-phosphate (S1P) et dau moins un agent chimiothérapique choisi dans le groupe comprenant des agents antimicrotubules fournit un traitement étonnamment supérieur du cancer. Des agents antimicrobiens tels que les composés du taxane sont connus dans lart, par exemple, le paclitaxel (disponible sous le nom TAXOL® chez Bristol-Myers Squibb, Princeton, NJ.), le docetaxel (disponible sous le nom TAXOTERE® chez Sanofi-aventis, Bridgewater, NJ.) et equivalents et dautres composés qui agissent comme des agents antimicrotubules, tels que la Vincristine (ONCOVIN®, VINCASAR PFS®, VCR), la Vinblastine (VELBAN®, VELSAR®) et la Vinorelbine, et des composés similaires. La présente invention concerne également des procédés de modulation de la croissance de populations cellulaires choisies, telles que les cellules cancéreuses, en administrant une quantité thérapeutiquement efficace dau moins un antagoniste du récepteur de la sphingosine-1-phosphate 1 (S1P1R), et dau moins un agent antimicrotubule.
Bentzien Frauke
Lamb Peter
Matthews David
Shankar Geetha
Bennett Jones Llp
Exelixis Inc.
LandOfFree
Synergistic effects between sphingosine-1-phosphate receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Synergistic effects between sphingosine-1-phosphate receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Synergistic effects between sphingosine-1-phosphate receptor... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1389813